MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Abstract

PURPOSE The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter is predictive for benefit from temozolomide in glioblastoma. A clinically optimized cutoff was sought allowing patient selection for therapy without temozolomide, while avoiding to withhold it from patients who may potentially benefit. EXPERIMENTAL DESIGN Quantitative MGMT methylation-specific PCR data were obtained for newly diagnosed glioblastoma patients screened or treated with standard radiotherapy and temozolomide in four randomized trials. The pooled dataset was randomly split into a training and test dataset. The unsupervised cutoff was obtained at a 50% probability to be (un)methylated. Receiver operating characteristics (ROC) analysis identified an optimal cutoff supervised by overall survival (OS). RESULTS For 4041 patients valid MGMT results were obtained, whereof 1725 were randomized. The unsupervised cutoff in the training dataset was 1.27 (log2[1000x(MGMT+1)/ACTB]), separating unmethylated and methylated patients. The optimal supervised cutoff for unmethylated patients was -0.28 (AUC=0.61), classifying "truly unmethylated" (-0.28) and "grey zone" patients (>-0.28, 1.27), the latter comprising 10% of cases. In contrast, for MGMT methylated patients (>1.27) more methylation was not related to better outcome. Both methylated and grey zone patients performed significantly better for OS than truly unmethylated patients (HR=0.35, 95% CI: 0.27-0.45, p<0.0001; HR=0.58, 95% CI: 0.43-0.78, p<0.001), validated in the test dataset. The MGMT assay was highly reproducible upon retesting of 218 paired samples (R2=0.94). CONCLUSIONS Low MGMT methylation (grey zone) may confer some sensitivity to temozolomide treatment, hence the lower safety margin should be considered for selecting unmethylated glioblastoma patients into trials omitting temozolomide. AbstractPurpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter is predictive for benefit from temozolomide in glioblastoma. A clinically optimized cutoff was sought allowing patient selection for therapy without temozolomide, while avoiding to withhold it from patients who may potentially benefit. Experimental Design: Quantitative MGMT methylation-specific PCR data were obtained for newly diagnosed glioblastoma patients screened or treated with standard radiotherapy and temozolomide in four randomized trials. The pooled dataset was randomly split into a training and test dataset. The unsupervised cutoff was obtained at a 50% probability to be (un)methylated. Receiver operating characteristics (ROC) analysis identified an optimal cutoff supervised by overall survival (OS). Results:For 4041 patients valid MGMT results were obtained, whereof 1725 were randomized. The unsupervised cutoff in the training dataset was 1.27 (log 2 [1000x(MGMT+1)/ACTB]), separating unmethylated and methylated patients. The optimal supervised cutoff for unmethylated patients was -0.28 (AUC=0.61), classifying "truly unmethylated" (≤-0.28) and "grey zone" ...

Functional drug susceptibility testing based on biophysical measurements predicts patient outcome in glioblastoma patient-derived neurosphere models

“…This result suggests that GBM patients may also exhibit a continuous spectrum of cell-intrinsic TMZ sensitivity versus resistance, rather than the binary classification typically represented by the presence or absence of MGMT promoter methylation. The notion of a continuous spectrum of TMZ responsiveness is consistent with previous work showing that MGMT promoter methylation status is also continuously distributed across patients, and that there is not a clear, unambiguous level of methylation separating "methylated" from "unmethylated" patients (32). Furthermore, recent studies suggest that quantitative levels of MGMT methylation in gliomas may also correlate with the response to TMZ (33).…”

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

“…Grade III-IV gliomas should undergo testing for MGMT promoter methylation status, since MGMT promoter methylated tumors typically respond better to alkylating chemotherapy, compared with unmethylated tumors. 34,37,38,53 To date, there are no targeted agents that have shown improvement in OS in the treatment of glioblastoma. Nevertheless, molecular testing of glioblastomas is still encouraged by the panel, as patients with a detected driver mutation may be treated with a targeted therapy on a compassionate use basis, and these tests improve diagnostic accuracy and prognostic stratification.…”

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis

“… 24 It has been recommended to use a lower safety margin when interpreting the MSP results in clinical trials to avoid withholding TMZ from “low MGMT methylation” patients who may still benefit from this treatment. 25 Similar limitations apply to pyrosequencing: A recent study suggested that 17% achieved the highest precision for correlation with clinical outcomes, 26 whereas 8–10% has been widely used in clinical practice.…”